Australia will expand its Pharmaceutical Benefits Scheme listing for pembrolizumab on September 1, 2026, adding three cancer indications. The government expects about 700 people a year to benefit, but access will depend on the Australian scheme's prescribing conditions.
The International Medical Device Regulators Forum finalized 10 lifecycle principles for medical AI in January 2025. They show why access to insurance claims data does not by itself establish data quality or clinical performance.
Shionogi launched ENDEAVORRIDE in Japan on June 5, 2026 after Japanese regulators reviewed local and US clinical data. The company also holds Taiwan rights, but APPI News could not verify a Taiwan license or public filing.
The US Food and Drug Administration announced its first TEMPO participant on July 22, 2026 and now lists two manufacturers in the pilot. Their devices can enter Medicare-supported care through conditional enforcement discretion and real-world data collection, not a finding of effectiveness for the uses under review.
Root canal treatment removes inflamed or infected pulp, cleans and seals the canals, and preserves the outer tooth. The treated tooth can still develop decay or fracture, and the appropriate final restoration depends on its location and remaining structure.
OpenAI began rolling out Health in ChatGPT to US adults on July 23, 2026, with connections to Apple Health and supported medical records. Taiwan's My Health Bank SDK instead sends selected records to third-party apps after a government review, and new SDK applications are currently paused.
Taiwan-listed Bionime secured a local medical-device license for its iFree2 continuous glucose monitor in April 2026, but the public notice did not identify an AI forecasting feature. Abbott's Libre Assist offers such predictions in the United States, while Abbott's Taiwan product site lists an older sensor and does not advertise the feature.
Decay, infection, cysts and damage to a neighboring tooth can make wisdom-tooth removal appropriate. For symptom-free, disease-free impacted teeth, evidence does not establish that routine removal is better than monitoring.
Taiwan's national health insurer is targeting older adults who use three or more sleeping medicines for extended periods. The review combines prescription oversight with sleep assessments, while evidence links some sedative combinations to fall-related hospital admissions.
Taiwan's health insurance agency said in August 2024 that it aimed to finish a cost-effectiveness review of AI diagnostic tools by the end of that year. APPI News could not find a published payment decision for the proposed CT brain-scan application as of August 3, 2026.
A dental implant quote can cover several clinical and laboratory stages rather than one replacement tooth. Implant and crown materials matter, but bone grafting, case complexity and long-term maintenance can also change the total.
The US Food and Drug Administration cleared UpDoc on December 23, 2025, as prescription software for adults with type 2 diabetes. Its chat interface collects patient data, while insulin instructions follow clinician-set treatment parameters.
A Taipei pharmacists' group and a private health association are expanding a program that links community pharmacies with clinics and corporate sponsors. The initiative proposes foot, bone and eye risk checks, but its promoters have not published test accuracy, referral completion or health-outcome data.
Taiwan's health ministry says three hospital groups completed a cross-system FHIR demonstration by the end of 2025. The standard can make records easier for software and AI tools to query, but it does not settle data quality, access control or accountability.
The World Health Organization and the International Telecommunication Union mapped the use of AI in traditional medicine in a 2025 technical brief. Their findings, combined with international medical-software standards, show why a product demonstration cannot establish clinical credibility.
The American Heart Association said in December 2025 that gum disease remains associated with cardiovascular disease, but evidence has not established cause and effect. By contrast, a 2022 Cochrane review found that treating periodontitis modestly improved blood glucose control in people with diabetes.
